Sentinel Node Mapping for Breast Cancer: Progress to Date and Prospects for the Future - 15/08/11
Corresponding author. John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404.Abstract |
Sentinel node biopsy (SNB) is indicated for women with small invasive breast cancers and clinically negative nodes. SNB indications are being expanded to larger breast tumors, some cases of ductal carcinoma in situ and selected clinically suspicious nodes. Because SNB has fewer and less severe complications than axillary lymph node dissection, physicians are exploring more ways it can be used to improve breast cancer treatment. The future of SNB includes resolution of the optimal timing of SNB in relation to neoadjuvant chemotherapy and the results of NSABP B-32 and ACOSOG Z10 and Z11. SNB has become the new standard of care for the treatment of early breast cancer.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by funding from the Ben B. and Joyce E. Eisenberg Foundation (Los Angeles, CA), the Fashion Footwear Association of New York Charitable Foundation (New York, NY), the Leslie and Susan Gonda (Goldschmied) Foundation (Los Angeles, CA), Avon Foundation (New York, NY), the John Wayne Cancer Institute Auxiliary (Santa Monica, CA), and the Associates for Breast and Prostate Cancer Studies (Santa Monica, CA). |
Vol 16 - N° 1
P. 55-70 - janvier 2007 Retour au numéro
Article précédent
- Sentinel Node Mapping for Melanoma: Results of Trials and Current Applications
- John F. Thompson, Helen M. Shaw
- Sentinel Node for Gastrointestinal Malignancies
- Yuko Kitagawa, Sukamal Saha, Atsushi Kubo, Masaki Kitajima
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?